Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederstatnews.com
STAT
Get the latest updates from STAT directly as they happen.
Follow now 228 followers
Latest posts
Last updated about 5 hours ago
Fraudulent citations, blamed on AI hallucinations, are becoming more common in research papers
about 5 hours ago
Citations in academic papers are intended to ground research in the work...
Key takeaways from WHO briefing on hantavirus cruise ship outbreak
about 7 hours ago
The MV Hondius, the cruise ship that has garnered global attention because...
Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles
about 9 hours ago
On this week’s episode of “The Readout LOUD,” we chat with Seaport...
Science is becoming less disruptive. Is an aging workforce to blame?
about 9 hours ago
Physicist Albert Einstein, widely regarded as one of the most prolific scientists...
Official leading CDC’s cruise ship program retires
about 10 hours ago
WASHINGTON — The top U.S. official responsible for public health on cruise...
STAT+: More political interference at the FDA?
about 12 hours ago
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about...
STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
about 13 hours ago
Top of the morning to you, and a fine one it is...
STAT+: FDA to reconsider treatment for rare cancer after surprise rejection
about 14 hours ago
Want to stay on top of the science and politics driving biotech...
STAT+: OpenAI’s health policy wishlist, CGM news from Dexcom, and more
about 14 hours ago
You’re reading the web edition of STAT’s Health Tech newsletter, our guide...
STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
about 15 hours ago
Two companies developing a therapy for a rare blood cancer have reached...
Hospital shootings steadily increased since 2000
about 16 hours ago
Good morning. I was charmed by this profile of tween life in...
STAT+: Next-gen Duchenne drug from Entrada disappoints
about 16 hours ago
Entrada Therapeutics’ next-generation drug for Duchenne muscular dystrophy disappointed in an early...